中文    ENGLISH
 
点击这里给我发消息 在线客服
Intermediates of API
Functional Chemicals 
 (S)-(-)-N,N-Dimethyl-3-hydroxy-3-(2-thienyl)propanamine
 (S)-N-methyl-3-hydroxy-3-(2-thienyl)propanamine
 (S)-1-(2,6-Dichloro-3-fluorophenyl)ethanol
 (R)-5-bromo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine
 (S)-1-Boc-3-hydroxypiperidine
 3,4-Dihydroxyphenylethanol
 4-Bromo-2-hydroxybenzoic acid
 2-Phenylpropionaldehyde
 2-Phenyl-1-propanol
 1,6-dihydro-6-oxo-3-pyridazinecarboxylic acid

About Us 

As an innovation-driven and customer-focused company, Specpharms Scientific Research Limited provides a broad and integrated portfolio of services throughout the pharmaceutical and nutraceutical R&D process. Our services are designed to help our customers shorten the discovery and development time and lower the cost of drug and diet supplement R&D through cost-effective and efficient outsourcing solutions.
Depending on the technology of asymmetric organic synthesis with enzymes, Specpharms has developed several series of chiral chemicals including chiral alcohols, chiral amines, chiral acids and unnatural amino acids. By applying this new technology to some particular functional groups , the chiral products were obtained with high chirality purity and perfect quality, meanwhile, the process of preparing these compounds were more environmental friendly and green.


Recomended Products
News
New Molecular Entity and New Therapeutic Biological Product Approvals for 2016
this site hacked by sir shahroukh
(R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethanol has been developed by Specpharms as a key intermediate for NK-1 receptor antagonist
New Molecular Entity and New Therapeutic Biological Product Approvals for 2015 (45 totally)
New Molecular Entity and New Therapeutic Biological Product Approvals for 2015

Copyright 2015 Specpharms Scientific Research Limited. All rights reserved. Supported by www.hxchem.net
Address: Suite 6, No. 888 Huide Rod, Jiading district, Shanghai 201806, P. R. China; Tel: +86 21 5997 1736 Fax: +86 21 6076 7136 E-mail: info@special-pharma.com